Selskabets formål er at etablere og/eller besidde filialer og ejerandele i selskaber i ind- og udland, at foretage investerings- og finansieringsvirksomhed, herunder anbringelse af kapital i virksomheder og fast ejendom i ind- og udland samt efter bestyrelsens nærmere bestemmelse at servicere sådanne selskaber og virksomheder driftsmæssigt. Selskabets formål er tillige at understøtte Novo Nordisk A/S farmaceutiske aktivitet.
| Year | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 2024 | 109.6 mio. | 2.3 mio. | 87.6 mio. | 31.2 mio. | 106 | |
CVR: 32657222
Compared to 68 companies in Formidlingsaktiviteter i forbindelse med specialiserede bygge- og anlægsarbejder
Comparison is based on industry median values
The financial health of NOVO NORDISK PHARMA OPERATIONS A/S appears stable, with a consistent revenue growth trend over the past five years, increasing from 79.2 million DKK in 2020 to 109.6 million DKK in 2024. Profitability has fluctuated, peaking at 5.0 million DKK in 2023 but declining to 2.3 million DKK in 2024, indicating potential concerns regarding profit margins. The company's equity has steadily improved, reaching 31.2 million DKK in 2024, which reflects a solid capital base. While the firm operates within a specialized construction sector, its profitability and revenue growth suggest a competitive position, although the recent profit decline warrants attention.
AI-generated summary
Companies in the same industry and area
companydata.dk